Cardiac AI: Validation Moats & Investor Value

In cardiovascular AI, the old saying “code is cheap, validation is expensive” is the absolute truth. While anyone can replicate the basic algorithms for image analysis or physiological signal processing, the creation of a massive, peer-reviewed clinical validation dataset is the real barrier to entry. Late-stage healthcare investors and growth equity partners evaluating diagnostic AI have to get this. The valuation floor for a pre-IPO AI health company in this space isn’t its software. It’s the defensibility built from a mountain of rigorous, large-scale clinical evidence.

Clinical Validation Builds Data Moats

The path from a cool AI concept to a commercially viable, reimbursed diagnostic tool is a gauntlet of clinical trials. Medical AI, especially Software as a Medical Device (SaMD), operates under heavy regulatory oversight that you just don’t see in general-purpose AI. An FDA 510(k) cleared indication is just table stakes. Real market leadership is forged by slogging through huge, multi-center studies proving real-world efficacy and an actual impact on patient outcomes. This process establishes the data moat: a competitive advantage from proprietary datasets that are incredibly expensive and time-consuming for anyone else to replicate. In cardiovascular AI, the software is the easy part. The hard part is the deep, longitudinal data needed to train and validate these models for something as complex as coronary artery disease. That data, often collected over years from diverse patient populations and verified by expert cardiologists, is what makes an AI trustworthy and clinically useful. Without it, the most elegant algorithm is just an academic project, completely unable to influence how doctors practice or convince health plans to pay for it.

Cleerly and HeartFlow: Benchmarking Validation Scale

To see what this scale of validation actually looks like, just look at the strategies of two of the biggest players in cardiovascular AI diagnostics: Cleerly and HeartFlow. Both companies got major traction by focusing on advanced analysis of coronary computed tomography angiography (CCTA) data, though they target different primary endpoints. HeartFlow, which pioneered fractional flow reserve from CT (CT-FFR), built its market position with extensive clinical registries and major trials. Cleerly which focuses on a detailed analysis of coronary plaque, has done the same, investing heavily in large, multi-center trials. HeartFlow’s evidence package is strong, built on studies that proved the accuracy and clinical utility of CT-FFR for identifying significant coronary artery disease by comparing it to the gold standard, invasive FFR. Their early trials used patient cohorts in the hundreds and thousands. More recently, their Plaque Analysis platform is being validated in huge real-world studies like the DECIDE Registry, which is enrolling about 22,000 patients across more than 30 centers in the U.S. All told, HeartFlow’s AI has been validated in over 200 studies looking at more than 365,000 patients ClinicalTrials.gov registry for HeartFlow trials. This massive body of evidence is what let them secure multiple FDA 510(k) clearances and set the precedent for getting AI diagnostics into cardiology workflows. And with over 625 peer-reviewed publications, the platform’s scientific credibility is hard to question. Cleerly took a similar, data-heavy path but focused on a more granular assessment of coronary plaque. Their approach of quantifying plaque volume and type, which goes way beyond the traditional way of just looking at stenosis, demands an equally tough validation process. Cleerly is running large-scale multi-center trials like the CONFIRM2 study to validate its plaque analysis against intravascular imaging. The CONFIRM2 registry is an international observational study targeting 30,000 patients, with over 10,750 already enrolled. Cleerly’s science is grounded in millions of images from over 40,000 patients across many institutions, which helps ensure it’s generalizable and not biased ClinicalTrials.gov registry for Cleerly trials. The company’s growing list of papers in major cardiology journals shows its commitment to evidence-based medicine. The difference between these established players and a typical startup is precisely this scale of validation. A startup can show promising accuracy on a small, retrospective dataset, but turning that into a product with regulatory approval, strong reimbursement, and widespread adoption requires an order of magnitude more investment in prospective, multi-center clinical trials.

Regulatory and Commercial Moats: The Twin Pillars of Defensibility

A complete clinical evidence package creates two moats at once: one for regulators and one for the market.

Regulatory Moat: Working through the FDA Field

For any diagnostic AI, getting that first FDA 510(k) clearance is a huge milestone. But keeping that clearance and expanding its indications requires constant validation. Companies sitting on piles of clinical data have an easier time responding to regulatory questions, supporting post-market surveillance, and even pursuing more ambitious pathways like a De Novo classification or a Breakthrough Device Designation for life-threatening conditions. When the American Heart Association and American College of Cardiology update their clinical guidelines, AI tools with strong evidence that lines up with those guidelines are the ones that get integrated and recommended. The FDA is also evolving its framework for AI/ML devices, and its concept of Predetermined Change Control Plans (PCCP) really benefits companies that already have mature data governance and validation pipelines. A strong evidence base allows for a much more predictable and simplified way to handle model updates, avoiding the need for a new 510(k) submission for every minor algorithmic tweak. That kind of regulatory agility offers a huge competitive advantage.

Commercial Moat: Health Plan Penetration and Enterprise Contracts

After you get past the regulators, the real test of a diagnostic AI company’s defensibility is whether you can secure broad health plan penetration and enterprise contracts. Payers and health systems are sophisticated and demand demonstrable improvements in patient outcomes, cost-effectiveness, and clinical workflow integration. For instance, HeartFlow’s Plaque Analysis platform got a Category I reimbursement code effective at the start of 2025, and Cigna announced it would cover it nationwide starting in October 2025. Cleerly has also secured Medicare coverage and a CPT Category I code for its advanced plaque analysis. Getting there requires:

• Outcomes Publication History: Peer-reviewed publications are essential tools for health economics and outcomes research (HEOR) teams to build reimbursement cases. They aren’t just academic exercises. They are what prove the tool improves patient management or reduces adverse events.
• Real-World Evidence (RWE): While key trials are essential, payers increasingly want RWE from electronic health records, registries, and claims data. Companies that can generate and analyze RWE to show ongoing value in diverse clinical settings build stronger cases for coverage and payment.
• Provider Adoption: Running large-scale clinical trials often involves leading academic medical centers and key opinion leaders. This early adoption by influential institutions is a powerful endorsement that can drive broader market acceptance and convince other health systems to integrate the tech.

Companies like HeartFlow and Cleerly, with their long publication records and deep trial portfolios, have a big advantage in these commercial talks. Their ability to point to clear, peer-reviewed evidence of clinical utility and patient benefit makes adoption a much lower risk for health systems and payers.

Investor Takeaway: Quantifying the Defensibility of Clinical Evidence

For late-stage healthcare investors and growth equity partners, evaluating diagnostic AI companies means looking past the flashy algorithms and digging into the clinical evidence. When you’re assessing a pre-IPO AI health company, ask these questions: 1. Scale and Scope of Clinical Trials: How many patients were in their key trials? Were they multi-center, prospective studies? Is the cohort size even in the same ballpark as what Cleerly or HeartFlow have? Larger, more diverse cohorts mean the AI is more strong and likely to work in the real world.

1. Longitudinal Outcomes Data: Does the company have data showing the long-term impact of its AI on patient outcomes, or is it just showing diagnostic accuracy at a single point in time? You need longitudinal data to prove sustained value and secure long-term reimbursement.
2. Peer-Reviewed Publication Volume: A strong publication history in top-tier cardiology journals (think Journal of the American College of Cardiology) is a good proxy for scientific rigor. This shows a commitment to evidence-based development and an ability to withstand scientific scrutiny.
3. FDA Clearances and Indications: What specific 510(k) clearances do they have? Are they pursuing a De Novo pathway for a truly new function? This is a good indicator of their regulatory maturity and strategic foresight.
4. Reimbursement Strategy and CPT Codes: While not directly tied to clinical evidence, a clear path to reimbursement is heavily dependent on it. Do they have a strategy for getting paid, like using existing CPT codes or going after new Category III codes? A strategy without strong data is just a dream. The tech is the spark, but in cardiovascular AI detection, rigorous, large-scale clinical validation is the fuel that powers sustainable growth and creates insurmountable moats. Investors who prioritize companies with a deep commitment to generating and publishing high-quality clinical evidence will be the ones who identify the next generation of market leaders. Methodology and Source Note: This analysis is based on publicly available information, including listings on ClinicalTrials.gov for Cleerly and HeartFlow trials, as well as peer-reviewed publications found in major cardiovascular journals. You should always verify specific patient numbers and publication volumes through direct company disclosures and official registries.